Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Compared to TM, MA increased the odds of annual wellness visits and reduced Hispanic-White disparity in annual wellness visits.
Why it matters
Medicare Advantage enrollees with ADRD had higher continuity of care than Traditional Medicare enrollees, and Traditional Medicare lowered the odds of Black and Hispanic beneficiaries having an annual wellness visit. This is about care delivery and disparities by insurance type, not about treating, curing or preventing the disease.
-
Hospital dementia care discourse on Reddit advanced 4 negative sentiment themes: (1) fear of poor medication management, hydration, and hygiene, (2) loss of patient advocacy, (3) precipitation of advance directive discussions, and (4) delayed discharge and loss of nursing home bed.
Why it matters
This analysis of Reddit posts found that negative sentiment posts about hospital dementia care during the COVID-19 pandemic outnumbered positive ones. The negative themes concerned medication management, hydration and hygiene, loss of patient advocacy, advance directive discussions, and delayed discharge.
-
We demonstrate the performance of our approach via simulation and application to vaccination coverage and HIV prevalence data from the Demographic and Health Surveys.
Why it matters
This paper proposes a statistical model to improve small-area estimates of health and demographic rates such as vaccination coverage and HIV prevalence. It provides no information on treating, curing or preventing Alzheimer's disease.
-
The 2014 Improving Medicare Post-Acute Care Transformation (IMPACT) Act systemized audits of long hospice stays, and the 2016 two-tier payment system decreased daily reimbursement rates after 60 days of enrollment.
Why it matters
This study examined how Medicare hospice policy changes related to live discharge rates and length of stay, including among patients with Alzheimer's disease and related dementias. It is about hospice payment policy, not about treating, curing, or preventing Alzheimer's disease.
-
Research on Area Deprivation Index (ADI) suggests that the built environment and neighborhood stressors (e.g., violent crime incidents) play a role in later-life cognitive function.
Why it matters
In this small study of 147 older African Americans, proximity to violent crime was a trending predictor of cognitive performance after adjusting for other factors. The result was only trending, not definitive, and the study concerns neighborhood stressors and cognition rather than treating, curing, or preventing Alzheimer's disease.
-
Patient satisfaction outcomes range from 71 - 100% with service intervention outcomes favourably indicating the direct impact of the service, which are unmeasurable to the older adult living with dementia, and include increases in: (i) Confidence - 90%; (ii) Mood - 50% and (iii) open to talking through difficulties encountered - 87%.
Why it matters
This describes a community post-diagnostic dementia support service delivered by an advanced nurse practitioner in Ireland, which reports increased quality-of-life outcomes and patient satisfaction. The service provides support from diagnosis onward but does not treat, cure, or prevent Alzheimer's disease.
-
Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA, was approved using the less common accelerated approval pathway by the Federal Drug Administration (FDA) reserved for treatments that fill a significant unmet need. 1 Its approval on June 7, 2021, has been met with an outpouring of opinions from prescribers, insurers, advocacy groups, and hospital systems regarding its risk-benefit profile. 2-4 Originally approved for all forms of Alzheimer disease (AD), the FDA updated aducanumab's labeling on July 8, 2021, for "treatment in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials." 5 With 6 million people nationally in the United States who suffer from AD and an anticipated one-third of those who may now fulfill the criteria under the revised labeling, the implicat
Why it matters
This paper describes practical considerations for neurologists administering aducanumab, which was approved through the FDA's accelerated approval pathway. It notes that approval was met with many opinions from prescribers, insurers, advocacy groups and hospital systems regarding the drug's risk-benefit profile.
-
Participants were 1060 Veterans (response rate of 20.14%), mean age of 68.39 (SD=8.52) years, 59.0% Caucasian, 69.2% non‐Hispanic, 95.8% male, 12.0% screened positive for MCI and 15.6% for dementia.
Why it matters
This study found that veterans living in the most deprived neighborhoods had a higher proportion of cognitive impairment compared to those in less deprived areas. It is a cross-sectional association and does not show that neighborhood deprivation causes dementia or that changing it would prevent the disease.
-
The outbreaks added significant additional stress to the nursing workforce, which has historically experienced high turnover, chronic staffing shortages, and increased burnout in long‐term care settings.
Why it matters
This qualitative study describes staff experiences of caring for residents with dementia during a COVID-19 outbreak in a long-term care home. It provides no information on treating, curing or preventing Alzheimer's disease.
-
The everyday landscape of occupational therapy (OT) in oncology is underexplored, hindering targeted improvements.
Why it matters
This survey described occupational therapy practice in oncology care, noting that cognitive impairment interventions were not directly billed. It concerns cancer care rather than Alzheimer's disease, so it has no direct implications for treating, curing or preventing dementia.
-
Practical implications With 100 percent foreign direct investment permitted in the F&G category in India, the research outcomes will be useful to all food retailers (prospective and current) interested in this retail market.
Why it matters
This study analyzed relationships between store attributes, satisfaction, patronage intention, and lifestyle in food and grocery store choice in India. It has no relevance to treating, curing, or preventing Alzheimer's disease.
-
Several existing systematic reviews have summarized the prevalence of dementia in mainland China, Hong Kong and Taiwan.
Why it matters
This updated review added 21 new studies to estimate dementia prevalence across regions of China, Hong Kong, and Taiwan. It found prevalence was lower in central, southern, Hong Kong, and Taiwan areas but higher in western China, and pooled estimates rose from pre-1990 to post-2010.
-
Previous research has revealed similarities in the neuropathology, clinical presentation, and risk factors between persons with Alzheimer disease from the general population (GP-AD) and those with Down syndrome (DS-AD).
Why it matters
This study compared cognitive profiles of people with Alzheimer's disease from the general population and people with Down syndrome and dementia, finding the profiles were very similar after adjusting for sex and functional impairment. It suggests the underlying dementia may have parallel effects on cognition but does not test any treatment or cure.
-
There was a 37.4% screen positive rate on the Mini-Cog.
Why it matters
This study found that routine cognitive screening in a neurology practice led to more follow-up cognitive assessments and more diagnoses of cognitive impairment or dementia. It concerns detection and diagnosis, not treating, curing or preventing Alzheimer's disease.
-
Compared with waiver enrollees, PACE enrollees had 31% lower risk of long-term NH admission (p < .001).
Why it matters
People enrolled in PACE had a 31% lower risk of long-term nursing home admission than those in 1915(c) waiver programs, even though they were more cognitively impaired at admission. PACE may be better suited to helping cognitively impaired people stay in the community longer.
-
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association is referred to as DSM-5™.
Why it matters
This text describes the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, noting that its predecessor DSM-III introduced specified diagnostic criteria that had a major impact on mental health. In DSM-5, these criteria were further updated to reflect gains in understanding of mental disorders.
-
Depression is a multicausal disorder and has been associated with the risk to develop cancer, dementia, diabetes, epilepsy and stroke.
Why it matters
This review states that depression is a multicausal disorder that has been associated with the risk of developing dementia, among other conditions. It reports no findings on treating, curing, or preventing Alzheimer's disease.
-
Based on physician medical records alone, the 231 high-risk participants (mean age 77, 67% women) received recommended care for 53% of 5,569 evaluated clinical circumstances, ranging from 12% for end-of-life care to 78% for diabetes mellitus.
Why it matters
This study measured the quality of care in a special needs plan using a nurse care manager model and found that recommended care was provided in fewer than 40% of clinical circumstances for dementia, falls, and urinary incontinence. It addresses care delivery for dementia but does not test any treatment, cure, or prevention for Alzheimer's disease.
-
It is well recognized that the number of older adults who suffer from dementia has been increasing and will continue to do so over the coming years.
Why it matters
This introduction describes the growing number of people with dementia in assisted living and nursing homes and the shift toward residential care settings. It addresses care settings and quality of life, not treatment, cure, or prevention of Alzheimer's disease.
-
Huntington's disease (HD) is a devastating neuropsychiatric disorder for which therapeutic interventions have been rather fruitless to date, except in a slight symptomatic relief.
Why it matters
This review of Huntington's disease found poor evidence for managing the condition, with no treatment recommendation of clinical relevance from the 24 best studies, and it recommends some drugs only based on open-label studies or case reports. It is about Huntington's disease, not Alzheimer's disease, and does not provide information on treating, curing or preventing Alzheimer's disease.
-
There is a limited choice of psychometric tests for Portuguese speaking people which have been evaluated in well defined groups.
Why it matters
This study applied a Portuguese version of the CERAD neuropsychological battery to healthy elderly people and Alzheimer's disease patients in Brazil and reported cut-off scores. It is a test-validation study and does not test any treatment, cure, or prevention.
-
This study adds further arguments for a cognitive impairment in MND/ALS.
Why it matters
Among 23 patients with motor neuron disease starting with bulbar symptoms, 11 were found to have cognitive impairment, and event-related potentials were the most sensitive test for it. This concerns cognitive impairment in motor neuron disease, not the treatment, cure or prevention of Alzheimer's disease.
-
Vascular dementia (VaD) is the second commonest subtype of dementia after Alzheimer's disease (AD).
Why it matters
This review found that the incidence of vascular dementia varied geographically even after accounting for differences in countries' age distributions, but it remains unclear whether this is due to genetic, environmental or methodological differences. It does not test a dementia treatment or cure.
-
This study investigated three aspects of processing materials with emotional content in patients with idiopathic Parkinson's disease (PD): the ability to produce affective prosody, to discriminate affectively loaded speech, and to detect the surprise element in humorous sketches.
Why it matters
This study found that Parkinson's disease patients with intact cognition were only impaired at producing emotionally loaded speech, while those with mental impairment were impaired on all emotional tasks. It is about emotional processing in Parkinson's disease and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
In 1986 in the Kuthar Valley in the Anantnag District of south Kashmir (northwestern India), we studied the population to ascertain the prevalence and pattern of various neurological diseases.
Why it matters
This house-to-house survey in rural Kashmir reported prevalence ratios for various neurological disorders and found no cases of Alzheimer's dementia. It describes disease occurrence and does not test any treatment, cure or prevention.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Autonomous unobtrusive detection of mild cognitive impairment in older adults
- The Effectiveness of the Comprehensive Dementia Prevention App 'MELI'
- Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition
- Caring While Moving: Case Studies on Physical Activity and Dementia Caregiver Well-Being
- Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes
- Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression
- Demographic, Health, and Social Predictors of Place of Death in England, 2004-2013: Identifying barriers to dying in the community
- Lifespan and Healthspan: Past, Present, and Promise
- Dementia After Moderate-Severe Traumatic Brain Injury: Coexistence of Multiple Proteinopathies
- Stakeholder Perspectives on Integrating ADEPT Into End‐Of‐Life Care for Nursing Home Residents With Dementia: A Qualitative Descriptive Study